NFE2L2 and liver dysplastic nodule: Numerous compounds that prevent DN through modulating the Nrf2 pathways, such as chlorogenic acid (CGA) and bardoxolone methyl, have already been tested in renal clinical trials (Thomas, 2012; Bao et al., 2018).